Adamant Health selected for AMPlify – Accelerated US Market Entry program 2024
Business Finland has announced the cohort for the AMPlify – Accelerated US Market Entry program 2024, and we are proud that Adamant Health is one of twelve selected Finnish healthcare companies for the program.
AMPlify is a market entry platform and comprehensive US healthcare ecosystem designed by Business Finland in collaboration with Mayo Clinic. The program aims to support Finnish healthcare companies in accessing the US market and shorten their time to market.
Mayo Clinic, the program partner, is the largest integrated, not-for-profit medical group practice in the world and one of the leading hospitals in the US. Mayo Clinic is committed to clinical practice, education, and research and aims to improve the health of communities and accelerate equality and diversity in health care. According to U.S. News & World Report, Mayo Clinic has more No. 1 rankings than any other hospital.
“Joining the program will enable us to gain valuable market and business insights and access to an invaluable network of high-level experts from the US market,” says Paulus Carpelan, CEO and Co-founder at Adamant Health. “We are looking forward to this exciting program and receiving guidance for a successful entry to the US market.”
“The program takes place at the right time for Adamant Health. President Biden signed on 2 July 2024 the National Plan to End Parkinson’s Act, a first-ever federal initiative to prevent and cure Parkinson’s disease, treat its symptoms and slow or stop its progression. Adamant Health proudly shares these goals,” continues Anne Räsänen, Director, Business Development at Adamant Health.
Parkinson’s disease is the fastest-growing neurological disorder globally. In the US, nearly 90,000 people are diagnosed with Parkinson’s disease every year. According to the Parkinson’s Foundation Parkinson’s Prevalence Project, 1.2 million people in the US will be living with Parkinson’s by 2030.
Adamant Health has developed the first, advanced precision technology able to measure the visible and invisible motor symptoms of Parkinson’s disease. Our unique CE-marked data-analysis technology, based on surface electromyography (EMG) and kinematic measurement, provides detailed and accurate symptom data – essential for supporting personalized treatment that can be continuously optimized. We are helping clinicians to make more informed treatment decisions for their patients!